Université de Paris, Institut Cochin, CNRS, INSERM, F- 75014 Paris, France; Hôpital Cochin, 24, rue du Faubourg Saint Jacques, 75014 Paris, France
Marion Régnier
UCLouvain, Université catholique de Louvain, Walloon Excellence in Life Sciences and BIOtechnology, Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Brussels, Belgium
Hervé Guillou
Toxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse 31027, France
Catherine Postic
Université de Paris, Institut Cochin, CNRS, INSERM, F- 75014 Paris, France; Corresponding author. Address: Institut Cochin - 24 rue du Faubourg Saint-Jacques, France.
Summary: Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD. In this review, we will provide an update on the known molecular pathways involved in the pathophysiology of NAFLD and on ongoing studies of new therapeutic targets.
